Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Stem cell-derived angiogenic long non-coding RNA (SCDAL)
- Target
- SCDAL
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
Stem cell-derived angiogenic long non-coding RNA (SCDAL), also known as AC103746.1, is a human/primate-specific lncRNA highly expressed in human embryonic stem cell-derived mesenchymal stem cells. SCDAL is a critical upstream regulator of angiogenesis, functioning via trans-activation of growth differentiation factor 6 (GDF6) expression—mediated by recruitment of SNF5 to the GDF6 promoter—which leads to paracrine stimulation of endothelial cell angiogenesis through a VEGFR2-dependent pathway. SCDAL knockdown reduces and its overexpression enhances angiogenic and reparative functions, particularly relevant to cardiac ischemia and tissue repair. This RNA is a representative example of regulatory non-coding RNAs with identified therapeutic target potential in cardiovascular disease settings[1][3][5].
- Other names
- SCDALAC103746.1stem cell-derived angiogenic lncRNA
02
Mechanism of action
Induces growth differentiation factor 6 (GDF6) expression via direct interaction with the chromatin modifier SNF5 at the GDF6 promoter Paracrine promotion of endothelial angiogenesis via GDF6-mediated non-canonical vascular endothelial growth factor receptor 2 (VEGFR2) activation
03
Biological functions
Regulation of angiogenesisParacrine signalingRegulation of gene expression (trans-acting modulation)Enhancement of endothelial cell angiogenic potential
04
Disease associations
Cardiovascular disease (myocardial infarction, ischemic heart disease)Other (potential relevance in tissue repair and regeneration)
05
Safety considerations
No specific safety concerns or therapeutic challenges identified in current literature; as a regulatory RNA rather than a druggable protein, standard drug-target safety concerns (like off-target effects or toxicity) are less established
Beyond the preview
Go deeper on Stem cell-derived angiogenic long non-coding RNA (SCDAL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stem cell-derived angiogenic long non-coding RNA (SCDAL).